SWS Medical(SH:688410) Xin Lang Cai Jing·2025-11-12 02:03Core Viewpoint - The stock of Chongqing Shanwaishan Blood Purification Technology Co., Ltd. has shown significant price movements and financial growth, indicating potential investment opportunities in the medical device sector [1][2]. Company Overview - Chongqing Shanwaishan was established on March 26, 2001, and listed on December 26, 2022. The company specializes in the research, production, and sales of blood purification equipment [1]. - The company's revenue composition includes 66.12% from blood purification equipment, 23.89% from blood purification consumables, 8.31% from medical services, and 1.68% from other sources [1]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 584 million yuan, representing a year-on-year growth of 39.79%. The net profit attributable to shareholders was 104 million yuan, reflecting a year-on-year increase of 68.68% [2]. - As of September 30, 2025, the company has distributed a total of 104 million yuan in dividends since its A-share listing [3]. Stock Performance - As of November 12, the stock price increased by 2.06% to 16.84 yuan per share, with a total market capitalization of 5.411 billion yuan. The stock has risen by 52.26% year-to-date, although it has seen a decline of 2.15% in the last five trading days [1]. - The stock's trading volume on November 12 was 18.742 million yuan, with a turnover rate of 0.48% [1]. Shareholder Information - The number of shareholders increased by 26.20% to 10,300 as of September 30, 2025, while the average circulating shares per person decreased by 20.76% to 22,805 shares [2]. - Notable institutional shareholders include Penghua Medical Technology Stock A and Bosera Healthcare Mixed A, holding 5.182 million shares and 3.257 million shares, respectively [3].